Natera, Inc. announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). This trial will prospectively incorporate Signatera, Natera’s personalized, tumor-informed molecular residual disease (MRD) test.
The ARCHER study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care for MIBC. Signatera will be used for MRD monitoring within this significant clinical trial.
The selection of Signatera for this NRG-sponsored trial underscores its growing importance in guiding treatment decisions and monitoring disease status in bladder cancer. This further integration into major clinical research is expected to expand Signatera's clinical utility and adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.